Anthera Pharmaceuticals Inc (NASDAQ:ANTH), today announced that it has completed the previously announced underwritten public offering of 3,833,334 shares of its common stock, offered at a price of $7.50 per share, which includes the exercise in full by the underwriters of their option to purchase 500,000 additional shares of common stock. The aggregate gross proceeds to the Company from the sale of shares in this offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, are approximately $28.8 million. Anthera intends to use the net proceeds from this offering for clinical research and development and general corporate purposes.
Citigroup Global Markets Inc. and Piper Jaffray & Co. acted as joint book-running managers for the offering. SunTrust Robinson Humphrey acted as co-manager. (Original Source)
Shares of Anthera Pharmaceuticals opened today at $8.07 and are currently trading up at $8.6325. ANTH has a 1-year high of $9.89 and a 1-year low of $1.46. The stock’s 50-day moving average is $7.70 and its 200-day moving average is $4.87.
Anthera Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapeutics to treat serious diseases associated with inflammation and autoimmune diseases.